2023-12-05 13:00
Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum® TKa will be presented at the world's largest breast cancer symposium, SABCS, in early December. New clinical research for...
2023-12-01 08:00
Biovica, active in cancer diagnostics, today announces that the company has received a license for Maryland state, the 18th largest state in the US. The license means that Biovica can now perform analysis and report patient samples from all US states...
2023-11-28 17:00
Stockholm, Sweden, November 28, 2023 – On October 23, 2023, Biovica International AB (publ) (“Biovica” or the “Company”) (Nasdaq First North Premier Growth Market: BIOVIC B) announced that the Board of Directors has resolved...
2023-11-28 08:00
Continued sales growth and several commercial agreements signed! Significant events during the second quarter Significant events after the end of the period Webcast:When: 28/11 2023 kl. 15.00 CETWhere: register via lyyti: https://www.lyyti.fi/reg/Biovica_Q2_Earnings_call_2023__Live_Event_2257Broadcast...
2023-11-24 12:30
Biovica, active in cancer diagnostics, publishes its interim report for the second quarter 2023/2024, on November 28 at 08:00 CET. The company invites you to a webcast on the same day at 15.00 CET. Anders Rylander, CEO, Warren Cresswell, President of...
2023-11-23 14:20
The extra general meeting of Biovica International AB (the "Company") was held today on 23 November 2023 and the following resolution was passed by the meeting. Amendments of the articles of association The extra general meeting resolved, in...
2023-11-21 10:00
Biovica, active in cancer monitoring, today announces that the Center for Medicare & Medicaid Services (CMS) after reviewing public comments, has agreed with the minority CDLT panel to crosswalk DiviTum TKa to reimbursement code 0058U. The comments...
2023-11-13 08:00
Today, Biovica, active in cancer monitoring, announces that the company has signed a commercial partnership agreement for the Nordics with Axlab A/S to commercialize the DiviTum® TKa assay. “Axlab is a top-5 brand in cancer screening and diagnostics...
2023-10-23 08:01
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting to be held on Thursday 23 November 2023, at 14:00 CET at Baker McKenzie Advokatbyrå's offices on Vasagatan...
2023-10-23 08:00
INSIDE INFORMATION: Stockholm, Sweden, October 23, 2023 – The Board of Directors of Biovica International AB (publ) (“Biovica” or the “Company”) (Nasdaq First North Premier Growth Market: BIOVIC B) has resolved to conduct...
>4,500
Numbers of patients in studies
28
Publications
19
Pharma Projects